Pharmacotherapy for alcohol dependence: Status of current treatments

Current Opinion in Neurobiology

Volumn 23, Issue 4, 2013, Pages 692-699

  Franck, Johan ^a   Jayaram Lindström, Nitya ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; ACAMPROSATE; BACLOFEN; DISULFIRAM; GABAPENTIN; LY 686017; NALMEFENE; NALTREXONE; NEUROKININ 1 RECEPTOR ANTAGONIST; PEXACERFONT; PLACEBO; PRAZOSIN; PREGABALIN; TOPIRAMATE; UNCLASSIFIED DRUG; VARENICLINE; VERUCERFONT;

ALCOHOLISM; AREA UNDER THE CURVE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RELEASE; DRUG RESPONSE; DRUG TOLERABILITY; EXTENDED DRUG RELEASE; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; GABAERGIC TRANSMISSION; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NEUROTRANSMISSION; PARESTHESIA; PATIENT COMPLIANCE; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; WITHDRAWAL SYNDROME;

EID: 84881240952     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2013.05.005     Document Type: Review

References (100)

1. Grant B.F., Stinson F.S., Dawson D.A., Chou S.P., Dufour M.C., Compton W. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:807-816.
2. WHO Global Status Report on Alcohol and Health Analysis 2011, World Health Organisation, Geneva.
3. Rehm J., Mathers C., Popova S., et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorder. Lancet 2009, 373:2223-2233.
4. European Medicines Agency European Medicines Agency Recommends Approval of Medicine for Reduction of Alcohol Consumption 2012, http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/news_and_events/news/2012/12/news_detail_001675.jsp%26mid=WC0b01ac058004d5c1.
5. Johnson B.A. Medication treatment of different types of alcoholism. Am J Psychiatry 2010, 167:630-639.
6. O'Malley S.S., O'Connor P.G. Medications for unhealthy alcohol use. Alcohol Res Health 2011, 33:300-312.
7. Kranzler H.R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001, 25:1335-1341.
8. Hald J., Jacobsen E., Larsen V. The sensitizing effect of tetraethylthiuramdisulphide (antabuse) to ethylalcohol. Acta Pharmacol Toxicol (Copenh) 1948, 4:285-296.
9. Fuller R.K., Branchery L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacoursiere R.B., Lee K.K., Lowenstam I. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986, 256:1449-1455.
10. Chick J., Gough K., Falkowski W. Disulfiram treatment for alcohol dependence. Br J Psychiatry 1992, 161:84-89.
11. Treating Alcohol and Drug Abuse: An Evidence Based Review 2003, Wiley-VCH Verlag GmbH and Co., Weinheim. M. Berglund (Ed.).
12. Krampe H., Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010, 16:2076-2090.
13. Hertz A. Endogenous opioid system and alcohol addiction. Psychopharmacology (Berl) 1997, 129:99-111.
14. Gianoulakis C. Alcohol-seeking behavior. The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. Alcohol Health Res World 1998, 22:202-210.
15. O'Brien C.P., Volpicelli L.A., Volpicelli J.R. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996, 13:35.
16. Stromberg M.F., Mackler S.A. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited access procedure in rats. Pharmacol Biochem Behav 2002, 72:483-490.
17. Lee M.C., Wager H.N. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988, 29:1207-1211.
18. McCaul M.E., Wand G.S., Eissenberg T., Rohde C.A., Cheskin L.J. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000, 22:480.
19. Volpicelli J.R., Alterman A.L., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49:876-880.
20. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992, 49:881-887.
21. Streeton C., Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001, 36:544-552.
22. Bouza C., Angeles M., Muñoz A., Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004, 99:811-828. [Erratum, Addiction 2005;100:573].
23. Srisurapanont M., Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005, 8:267-280.
24. Krystal J.H., Cramer J.A., Krol W.F., Rosenheck R.A. Veterans affairs naltrexone cooperative study 425 group. N Engl J Med 2001, 345:1734-1739.
25. Balldin J., Berglund M., Borg S., Mansson M., Bedtsen P., Franck J., Gustafsson L., Halldin J., Nilsson L.H., Stolt G., Wilander A. A 6-month controlled naltrexone study: combined effect with cognitive behavior therapy in outpatient treatment of alcohol dependence. Alcohol: Clin Exp Res 2003, 27:1142-1149.
26. Monti P.M., Rohsenow D.J., Swift R.M., Gulliver S.B., Colby S.M., Mueller T.I. Naltrexone and cue exposure with coping and communications skills training for alcoholics: treatment process and 1-year outcomes. Alcohol: Clin Exp Res 2001, 25:1634-1647.
27. Oslin D.W., Berrettini W., Kranzler H.R. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
28. Anton R. Naltrexone for the management of alcohol dependence. N Engl J Med 2008, 359:715-721.
29. Chick J., Anton R., Checinski K., Croop R. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000, 35:587-593.
30. Volpicelli J.R., Rhines K.C., Rhines J.S. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997, 54:737-742.
31. ®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 2003, 28:1973-1982.
32. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.
33. Lewis D.H. Controlled release of bioactive agents from lactide/glycolide polymers. Biodegradable Polymers as Drug Delivery Systems 1990, 1-41. Marcel Dekker, New York. M. Chasin, R. Langer (Eds.).
34. Johnson B.A. Naltrexone long acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manage 2007, 3:741-749.
35. Dunbar J.D., Dunbar J.L., Turncliff R.Z., Dong Q., Silverman B.L., Ehrich E.W., Lasseter K.C. Single and multiple dose pharmacokinetics of long-acting naltrexone. Alcohol Clin Exp Res 2006, 30:480-490.
36. Gastfriend D. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 2011, 1216:144-166.
37. Pettinati H.M., Gastfriend D.R., Dong Q., Kranzler H.R., O'Malley Effect of extended release naltrexone (XR-NTX) on quality of life in alcohol dependent patients. Alcohol: Clin Exp Res 2009, 33:350-356.
38. Kranzler H.R., Wesson D.R., Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004, 28:1051-1059.
39. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., Loewy J.W., Ehrich E.W. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625. Vivitrex Study Group.
40. Garbutt J.C. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010, 16:2091-2097.
41. Emmerson P.J., Liu M.R., Woods J.H. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 1994, 271:1630-1637.
42. Ingman K., Hagelberg N., Aalto S. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005, 30:2245-2253.
43. Dixon R., Gentile J., Hsu H.B. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987, 27:233-239.
44. Gal T.J., DiFazio C.A. Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology 1986, 64:175-180.
45. Karhuvaara S., Simojoki K., Virta A., Rosberg M., Löyttyniemi E., Nurminen T., Kallio A. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol: Clin Exp Res 2007, 31:1179-1187.
46. Anton R.F., Pettinati H., Zweben A. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004, 24:421-428.
47. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 2009, 56:719-724.
48. Mann K., Bladström A., Torup L., Gual A., Van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013, 73:706-713.
49. Gual A, He Y, Torup L, Brink WM, Mann K, for the ESENSE2 Study Group: A randomised, double-blind, placebo-controlled, efficacy study of nalmefene as-needed use in patients with alcohol dependence. Eur Neuropsychopharmacol, 2013. doi:10.1016/j.euroneuro.2013.02.006.
50. Spanagel R., Sillaber I., Zieglgansberger W., Corrigall W.A., Stewart J., Shaham Y. Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology (Berl) 1998, 139:391-401.
51. De Witte P., Bachteler D., Spanagel R. Acamprosate: preclinical data. Drugs for Relapse Prevention of Alcoholism 2005, 73-83. Birkhäuser Verlag, Basel, Switzerland. R. Spanagel, K.F. Mann (Eds.).
52. Rossetti Z.L., Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 1995, 283:177-183.
53. Dahchour A., De Witte P., Bolo N., Nédélec J.F., Muzet M., Durbin P., Macher J.P. Central effects of acamprosate. Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998, 82:107-114.
54. Hammarberg A., Jayaram-Lindström N., Beck O., Franck J., Reid M.S. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 2009, 205:53-62.
55. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004, 28:51-63.
56. Mason B.J., Goodman A.M., Chabac S., Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006, 40:383-393.
57. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioural interventions for alcohol dependence-the COMBINE study: a randomized controlled trial. J Am Med Assoc 2006, 295:2003-2017. COMBINE Study Research Group.
58. Weiss R.D., O'Malley S.S., Hosking J.D., Locastro J.S., Swift R. Do patients with alcohol dependence respond to placebo? Results from the COMBINE study. J Stud Alcohol Drugs 2008, 69:878-884.
59. LoCastro J.S., Youngblood M., Cisler R.A., Mattson M.E., Zweben A., Anton R.F., Donovan D.M. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs 2009, 70:186-196.
60. Mann K., Lemenager T., Hoffmann S., Reinhard I., Hermann D., Batra A., Berner M., Wodarz N., Heinz A., Smolka M.N., Zimmermann U., Wellek S., Kiefer F., Anton R.F. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2012, The PREDICT Study Team. 10.1111/adb.12012.
61. Rösner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, CD004332.
62. Kranzler H.R., Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 2008, 17:70-76.
63. Kiefer F., Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des 2010, 16:2098-2102.
64. Maisel N.C., Blodgett J.C., Wilbourne P.L., Humphreys K., Finney J.W. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. Addiction 2013, 108:275-293.
65. Verheul R., Lehert P., Geerlings P.J., Koeter M.W., van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 2005, 178:167-173.
66. Mason B.J., Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012, 36:497-508.
67. Cruz H.G., Ivanova T., Lunn M.L., Stoffel M., Slesinger P.A., Lüscher C. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004, 7:153-159.
68. Muzyk A.J., Rivelli S.K., Gagliardi J.P. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. CNS Drugs 2012, 26:69-78.
69. Addolorato G., Caputo F., Capristo E. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002, 37:504-508.
70. Addolorato G., Leggio L., Ferrulli A. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007, 370:1915-1922.
71. Garbutt J.C., Kampov-Polevoy A.B., Gallop R. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo controlled trial. Alcohol Clin Exp Res 2010, 34:1-9.
72. Pastor A., Jones D.M., Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol 2012, 32:266-268.
73. Addolorato G., Leggio L., Ferrulli A. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011, 46:312-317.
74. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 2007, 42:158-160.
75. Amini M., Runyon B.A. Alcoholic hepatitis: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010, 16:4905-4912.
76. Rolland B., Bordet R., Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction 2012, 107:848-849. [Epub 2012 February 11]. 10.1111/j.1360-0443.2011.03752.x.
77. AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé. Utilisation hors AMM du baclofène dans le traitement de l'alcoolo-dépendance-point d'information 06/06/11 [Off-label use of baclofen in the treatment of alcohol-dependence. Information Point]. http://ansm.sante.fr/var/ansm_site/storage/original/application/b88517d4324d10054712c930f22c464b.pdf.
78. Johnson B.A. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005, 19:873-896.
79. Okada M., Yoshida S., Zhu G., Hirose S., Kaneko S. Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. Neuroscience 2005, 134:233-246.
80. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651. Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group.
81. Baltieri D.A., Daró F.R., Ribeiro P.L., de Andrade A.G. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103:2035-2044.
82. Flórez G., García-Portilla P., Alvarez S., Saiz P.A., Nogueiras L., Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 2008, 32:1251-1259.
83. Shinn A., Greenfield S. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010, 71:634-648.
84. Steensland P., Simms J.A., Holgate J., Richards J.K., Bartlett S.E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 2007, 104:12518-12523.
85. Mitchell J.M., Teague C.H., Kayser A.S., Bartlett S.E., Fields H.L. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012, 223:299-306.
86. Litten R.Z., Ryan M.L., Fertig J.B., Falk D.E., Johnson B., Dunn K.E., Green A.I., Pettinati H.M., Ciraulo D.A., Sarid-Segal O., Kampman K., Brunette M.F., Strain E.C., Tiouririne N.A., Ransom J., Scott C., Stout R. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013, [Epub ahead of print].
87. Söderpalm B., deBejczy A., Ericson M., Guterstam J., Hammarberg A., Franck J., Asanovska G., Löf E. The ethanol-nAChR interaction and its relevance for modulating ethanol consumption in rodents and man. Alcohol Clin Exp Res 2012, S202.
88. Lahti R.A., Tamminga C.A., Carlsson A. Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro. J Neural Transm 2007, 14:1143-1146.
89. Steensland P., Fredriksson I., Holst S., Feltmann K., Franck J., Schilström B., Carlsson A. The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry 2012, 72:823-831.
90. Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs 2012, 21:1243-1245.
91. Martinotti G., Di Nicola M., Tedeschi D., Andreoli S., Reina D., Pomponi M., Mazza M., Romanelli R., Moroni N., De Filippis R., Di Giannantonio M., Pozzi G., Bria P., Janiri L. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2010, 24:1367-1374.
92. Furieri F.A., Nakamura-Palacios E.M. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007, 68:1691-1700.
93. Anton R.F., Myrick H., Baros A.M., Latham P.K., Randall P.K., Wright T.M., Stewart S.H., Waid R., Malcolm R. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol 2009, 29:334-342.
94. Anton R.F., Myrick H., Wright T.M., Latham P.K., Baros A.M., Waid L.R., Randall P.K. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011, 168:709-717.
95. Sinha R. Modeling relapse situations in the human laboratory. Curr Top Behav Neurosci 2013, 13:379-402.
96. 1 receptor antagonists to treat alcoholism. Drug Alcohol Depend 2013, 128:175-186.
97. George D.T., Gilman J., Hersh J., Thorsell A., Herion D., Geyer C., Peng X., Kielbasa W., Rawlings R., Brandt J.E., Gehlert D.R., Tauscher J.T., Hunt S.P., Hommer D., Heilig M. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008, 319:1536-1539.
98. Rasmussen D.D., Alexander L.L., Raskind M.A., Froehlich J.C. The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 2009, 33:264-272.
99. Simpson T.L., Saxon A.J., Meredith C.W., Malte C.A., McBridge B., Fergursson A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 2009, 33:255-263.
100. Johnson B.A., Roache J.D., Javors M.A., DiClemente C.C., Cloninger C.R., Prihoda T.J., Bordnick P.S., Ait-Daoud N., Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000, 284:963-971.